Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Status:
Terminated
Trial end date:
2019-07-12
Target enrollment:
Participant gender:
Summary
Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using
recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation
due to development of tolerance or immunosuppression. This trial combines one drug from each
category, immunotherapeutic Nivolumab and chemotherapeutic gemcitabine as it was reported
that gemcitabine reduces immunosuppression by killing myeloid derived suppressor cells,
thereby increasing the efficacy of Nivolumab.